GIGA 2021 Annual Report 77 SELECTED PUBLICATIONS Novel Loss of Function Variant in BCKDK Causes a Treatable Developmental and Epileptic Encephalopathy. Boemer F, Josse C, Luis G, Emmanuel Di Valentin, Thiry J, Cello C, Caberg JH, Dadoumont C, Harvengt J, Lumaka A, Bours V, Debray FG. IntMol Sci. 2022 Feb 18;23(4):2253. Mapping the human genetic architecture of COVID-19. COVID-19 Host Genetics Initiative. Nature. 2021 Dec;600(7889):472-477. doi: 10.1038/s41586-021-03767-x. Epub 2021 Jul 8. Dual-specificity phosphatase 3 deletion promotes obesity, non-alcoholic steatohepatitis and hepatocellular carcinoma. Jacques S, Arjomand A, Perée H, Collins P, Mayer A, Lavergne A, Wéry M, Mni M, Hego A, Thuillier V, Becker G, Bahri MA, Plenevaux A, Di Valentin E, Oury C, Moutschen M, Delvenne P, Paquot N, Rahmouni S. Sci Rep. 2021 Mar 12;11(1):5817. Communicating hydrocephalus associated to ventral leptomeningeal invasion leads to precocious death in a glioblastoma orthotopic xenograft model. Lombard A, Digregorio M, Coppieters N, Di Valentin E, Hego A, Martin D, Rogister B. Neurooncol Adv. 2020 Aug 17;2(1):vdaa099 Metastatic colorectal cancer cells maintain the TGFβ program and use TGFBI to fuel angiogenesis. Chiavarina B, Costanza B, Ronca R, Blomme A, Rezzola S, Chiodelli P, Giguelay A, Belthier G, Doumont G, Van Simaeys G, Lacroix S, Yokobori T, Erkhem-Ochir B, Balaguer P, Cavailles V, Fabbrizio E, Di Valentin E, Gofflot S, Detry O, Jerusalem G, Goldman S, Delvenne P, Bellahcène A, Pannequin J, Castronovo V, Turtoi A. Theranostics. 2021 Jan 1;11(4):1626-1640. PDCLine PHARMA PDC*line Pharma is a Belgian-French biotech company that is developing a novel class of off-the-shelf cancer immunotherapies based on a proprietary Plasmacytoid Dendritic Cell line (PDC*line) preloaded with peptides that are derived from target tumor antigens. Based on a robust preclinical package and a first-in-human phase Ib feasibility study in melanoma, PDC*line Pharma is focusing on lung cancer with a new candidate in clinical development (PDC*lung) and on neoantigens (PDC*Neo). Installed in GIGA and located next door to the GIGA Viral Vectors platform, PDC Line Pharma has a strong and long-term collaboration with Emmanuel di Valentin and his team. The platform offers its expert and professional services to help PDC Line Pharma in the generation of its cellular immunotools by producing and amplifying plasmids, producing retrovirus and lentivirus vectors. The platform also performs mycoplasma routine testing for the company. Furthermore, PDC Line Pharma uses the BSL2 managed by the platform for the biosafety release of their cellular products.
RkJQdWJsaXNoZXIy MTk1ODY=